First 10 runs free
    Intelligence Feed event · Policy · 2026-10-26

    Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancer

    Question

    Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancer

    Direct answer

    Johnson & Johnson released Phase 1b/2 clinical data from the OrigAMI-4 study testing subcutaneous amivantamab in advanced recurrent or metastatic head and neck squamous cell carcinoma. The triplet regimen comprising amivantamab, pembrolizumab, and carboplatin achieved a 77% overall response rate among first-line patients. The study broadens clinical utility for the bispecific antibody outside its core EGFR non-small cell lung cancer indications.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-26
    Published
    2026-10-26
    Revision
    1 · 2026-10-28

    Cite as: Market Ontology, “Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancer”, revision 1, evidence through 2026-10-26. https://marketontology.com/market-events/2026-10-26/johnson-johnson-amivantamab-combo-reports-77-response-rate-in-head-and-neck-canc-ec9a10

    POLICY
    Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancer
    Johnson & Johnson released Phase 1b/2 clinical data from the OrigAMI-4 study testing subcutaneous amivantamab in advanced recurrent or metastatic head and neck squamous cell carcinoma. The triplet regimen comprising amivantamab, pembrolizumab, and carboplatin achieved a 77% overall response rate among first-line patients. The study broadens clinical utility for the bispecific antibody outside its core EGFR non-small cell lung cancer indications.
    JNJMRK
    Impact
    71
    OCT 26
    SIG
    88%
    JNJMRK
    Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancer
    Johnson & Johnson released Phase 1b/2 clinical data from the OrigAMI-4 study testing subcutaneous amivantamab in advanced recurrent or metastatic head and neck squamous cell carcinoma. The triplet regimen comprising amivantamab, pembrolizumab, and carboplatin achieved a 77% overall response rate among first-line patients. The study broadens clinical utility for the bispecific antibody outside its core EGFR non-small cell lung cancer indications.
    → High objective response rates in first-line HNSCC expand Rybrevant potential addressable market beyond EGFR non-small cell lung cancer into multi-indication solid tumor combinations.
    Impact
    Johnson & Johnson released Phase 1b/2 clinical data from the OrigAMI-4 study testing subcutaneous amivantamab in advanced recurrent or metastatic head and neck squamous cell carcinoma. The triplet regimen comprising amivantamab, pembrolizumab, and carboplatin achieved a 77% overall response rate among first-line patients. The study broadens clinical utility for the bispecific antibody outside its core EGFR non-small cell lung cancer indications.
    Affected
    JNJMRK
    Transmission
    High objective response rates in first-line HNSCC expand Rybrevant potential addressable market beyond EGFR non-small cell lung cancer into multi-indication solid tumor combinations.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    JNJpharmaceutical pipeline TAM expansion via multi-indication label developmentUp1-3mSubcutaneous amivantamab achieved a 77% overall response rate in first-line advanced head and neck squamous cell carcinoma.
    MRKcombination therapy demand pull-through for checkpoint inhibitor KeytrudaUp1-3mOrigAMI-4 study combined subcutaneous amivantamab with pembrolizumab.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    JNJUp266.30 2026-10-26PendingPendingPending
    MRKUpagreed140.61 2026-10-26+0.86%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    Find trades for this development

    Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.

    First 10 runs free

    First 10 runs free

    See today's live cards

    Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open live cards